A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
Young Do Kwon, Mangaiarkarasi Asokan, Jason Gorman, Baoshan Zhang, Qingbo Liu, Mark K. Louder, Bob C. Lin, Krisha McKee, Amarendra Pegu, Raffaello Verardi, Eun Sung Yang, VRC Production Program, Kevin Carlton, Nicole A. Doria‐Rose, Paolo Lusso, John R. Mascola, Peter D. Kwong
Abstract
of less than 1 μg/ml, with a half-life comparable to that of the parental VRC07-523LS. Our matrix-based structural approach thus enables the engineering of VRC01 variants for HIV-1 therapy and prevention with improved potency, breadth, and pharmacokinetics.
Topics & Concepts
AntibodyTrimerChemistryImmunologyVirologyMedicineDimerOrganic chemistryMonoclonal and Polyclonal Antibodies ResearchHIV Research and TreatmentComplement system in diseases